Advertisement

Supportive Care in Cancer

, Volume 20, Issue 6, pp 1135–1145 | Cite as

Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children—a systematic review of prospective trials

  • A. Manji
  • J. Beyene
  • L. L. Dupuis
  • R. Phillips
  • T. Lehrnbecher
  • L. SungEmail author
Review Article

Abstract

Background

There is no consensus on whether therapeutic intensity can be reduced safely in children with low-risk febrile neutropenia (FN). Our primary objective was to determine whether there is a difference in efficacy between outpatient and inpatient management of children with low-risk FN. Our secondary objective was to compare oral and parenteral antibiotic therapy in this population.

Methods

We performed electronic searches of Ovid Medline, EMBASE, and the Cochrane Central Register of Controlled Trials, and limited studies to prospective pediatric trials in low-risk FN. Percentages were used as the effect measure.

Results

From 7,281 reviewed articles, 16 were included in the meta-analysis. Treatment failure, including antibiotic modification, was less likely to occur in the outpatient setting compared with the inpatient setting (15 % versus 28 %, P = 0.04) but was not significantly different between oral and parenteral antibiotic regimens (20 % versus 22 %, P = 0.68). Of the 953 episodes treated in the outpatient setting and 676 episodes treated with oral antibiotics, none were associated with infection-related mortality.

Conclusion

Based on the combination of results from all prospective studies to date, outpatient and oral antibiotic management of low-risk FN are effective in children and should be incorporated into clinical care where feasible.

Keywords

Cancer Children Febrile Meta-analysis Neutropenia 

Notes

Acknowledgements

We would like to thank Elizabeth Uleryk for her gracious assistance and expertise in conduct of the literature search. We also would like to acknowledge Rhonda Adams for her administrative assistance.

LS is supported by a New Investigator Award with the Canadian Institutes of Health Research.

Conflict of interest

There are no conflicts of interest to declare.

References

  1. 1.
    Abbas AAH, Felimban SK, Cittana BA et al (2003) Once daily ceftriaxone and amikacin for outpatient treatment of neutropenic fever in children with acute lymphoblastic leukaemia. Haema 6(4):501–506Google Scholar
  2. 2.
    Ahmed N, El-Mahallawy HA, Ahmed IA, Nassif S, El-Beshlawy A, El-Haddad A (2007) Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatr Blood Cancer 49:786–792PubMedCrossRefGoogle Scholar
  3. 3.
    Ammann RA, Bodmer N, Hirt A et al (2010) Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol 28:2008–2014PubMedCrossRefGoogle Scholar
  4. 4.
    Ammann RA, Simon A, de Bont ES (2005) Low risk episodes of fever and neutropenia in pediatric oncology: is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer 45:244–247PubMedCrossRefGoogle Scholar
  5. 5.
    Aquino VM, Herrera L, Sandler ES, Buchanan GR (2000) Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 88:1710–1714PubMedCrossRefGoogle Scholar
  6. 6.
    Bartolozzi S, Clerico A, Properzi E, Minori A, Castello MA (1997) Ceftriaxone as a single agent in empirical therapy of unexplained fever in granulocytopenic children with solid tumors. J Chemother 9:227–231PubMedGoogle Scholar
  7. 7.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340PubMedGoogle Scholar
  8. 8.
    Boragina M, Patel H, Reiter S, Dougherty G (2007) Management of febrile neutropenia in pediatric oncology patients: a Canadian survey. Pediatr Blood Cancer 48:521–526PubMedCrossRefGoogle Scholar
  9. 9.
    Cagol AR, Castro Junior CG, Martins MC et al (2009) Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J Pediatr (Rio J) 85:531–535Google Scholar
  10. 10.
    Carstensen M, Sorensen JB (2008) Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 6:199–208PubMedGoogle Scholar
  11. 11.
    Chamberlain JD, Smibert E, Skeen J, Alvaro F (2005) Prospective audit of treatment of paediatric febrile neutropenia in Australasia. J Paediatr Child Health 41:598–603PubMedCrossRefGoogle Scholar
  12. 12.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  13. 13.
    Duzova A, Kutluk T, Kanra G et al (2001) Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 43:105–109PubMedGoogle Scholar
  14. 14.
    El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L (2011) Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 57:283–288Google Scholar
  15. 15.
    Freifeld A, Marchigiani D, Walsh T et al (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311PubMedCrossRefGoogle Scholar
  16. 16.
    Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93PubMedCrossRefGoogle Scholar
  17. 17.
    Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S (2009) Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 31:635–641PubMedCrossRefGoogle Scholar
  18. 18.
    Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437PubMedGoogle Scholar
  19. 19.
    Higgins JPT, Green S, Cochrane Collaboration (2008) Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell, Chichester; HobokenCrossRefGoogle Scholar
  20. 20.
    Kamboj M, Sepkowitz KA (2009) Nosocomial infections in patients with cancer. Lancet Oncol 10:589–597PubMedCrossRefGoogle Scholar
  21. 21.
    Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R (1994) Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 30:649–651PubMedGoogle Scholar
  22. 22.
    Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341:312–318PubMedCrossRefGoogle Scholar
  23. 23.
    Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMedGoogle Scholar
  24. 24.
    Kutluk T, Kurne O, Akyuz C et al (2004) Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer 42:284–286PubMedCrossRefGoogle Scholar
  25. 25.
    Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174PubMedCrossRefGoogle Scholar
  26. 26.
    Malik IA (1997) Out-patient management of febrile neutropenia in indigent paediatric patients. Ann Acad Med Singap 26:742–746PubMedGoogle Scholar
  27. 27.
    Moher D, Pham B, Klassen TP et al (2000) What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 53:964–972PubMedCrossRefGoogle Scholar
  28. 28.
    Mullen CA, Petropoulos D, Roberts WM et al (1999) Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86:126–134PubMedCrossRefGoogle Scholar
  29. 29.
    Mustafa MM, Aquino VM, Pappo A, Tkaczewski I, Buchanan GR (1996) A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 128:847–849PubMedCrossRefGoogle Scholar
  30. 30.
    Oude Nijhuis C, Kamps WA, Daenen SM et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23:7437–7444PubMedCrossRefGoogle Scholar
  31. 31.
    Paganini H, Gomez S, Ruvinsky S et al (2003) Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 97:1775–1780PubMedCrossRefGoogle Scholar
  32. 32.
    Paganini H, Rodriguez-Brieshcke T, Zubizarreta P et al (2001) Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 91:1563–1567PubMedCrossRefGoogle Scholar
  33. 33.
    Petrilli A, Altruda Carlesse F, Alberto Pires Pereira C (2007) Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. Pediatr Blood Cancer 49:682–686PubMedCrossRefGoogle Scholar
  34. 34.
    Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A (2000) Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 34:87–91PubMedCrossRefGoogle Scholar
  35. 35.
    Phillips B, Selwood K, Lane SM, Skinner R, Gibson F, Chisholm JC (2007) Variation in policies for the management of febrile neutropenia in United Kingdom Children’s Cancer Study Group centres. Arch Dis Child 92:495–498PubMedCrossRefGoogle Scholar
  36. 36.
    Phillips B, Wade R, Stewart LA, Sutton AJ (2010) Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 46:2950–2964PubMedCrossRefGoogle Scholar
  37. 37.
    Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332PubMedCrossRefGoogle Scholar
  38. 38.
    Rondinelli PI, Ribeiro Kde C, de Camargo B (2006) A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 28:665–670PubMedCrossRefGoogle Scholar
  39. 39.
    Santolaya ME, Alvarez AM, Aviles CL et al (2004) Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22:3784–3789PubMedCrossRefGoogle Scholar
  40. 40.
    Schimpff S, Satterlee W, Young VM, Serpick A (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:1061–1065PubMedCrossRefGoogle Scholar
  41. 41.
    Shrestha PN, Sah KP, Rana R (2009) Emperical oral antibiotic therapy for children with low risk febrile neutropenia during cancer chemotherapy. J Nepal Paediatr Soc 29(1):22–25Google Scholar
  42. 42.
    Speyer E, Herbinet A, Vuillemin A, Chastagner P, Briancon S (2009) Agreement between children with cancer and their parents in reporting the child’s health-related quality of life during a stay at the hospital and at home. Child Care Health Dev 35(4):489–495PubMedCrossRefGoogle Scholar
  43. 43.
    Sung L, Feldman BM, Schwamborn G et al (2004) Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents’ and healthcare professionals’ preferences. J Clin Oncol 22:3922–3929PubMedCrossRefGoogle Scholar
  44. 44.
    Teuffel O, Amir E, Alibhai SM, Beyene J, Sung L (2011) Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 127:e279–e286PubMedCrossRefGoogle Scholar
  45. 45.
    Teuffel O, Ethier MC, Alibhai SM, Beyene J, Sung L (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 11:2358–2365CrossRefGoogle Scholar
  46. 46.
    Vidal L, Paul M, Ben-Dor I, Pokroy E, Soares-Weiser K, Leibovici L (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev: CD003992Google Scholar
  47. 47.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344–349CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • A. Manji
    • 1
    • 2
  • J. Beyene
    • 3
    • 4
    • 5
  • L. L. Dupuis
    • 1
    • 6
    • 7
  • R. Phillips
    • 8
  • T. Lehrnbecher
    • 9
  • L. Sung
    • 1
    • 3
    • 5
    Email author
  1. 1.Division of Haematology/OncologyThe Hospital for Sick ChildrenTorontoCanada
  2. 2.Division of Clinical Pharmacology & ToxicologyThe Hospital for Sick ChildrenTorontoCanada
  3. 3.Program in Child Health Evaluative SciencesThe Hospital for Sick ChildrenTorontoCanada
  4. 4.Program in Population Genomics, Department of Clinical Epidemiology & Biostatistics, Faculty of Health SciencesMcMaster UniversityHamiltonCanada
  5. 5.Department of Health Policy, Management and EvaluationUniversity of TorontoTorontoCanada
  6. 6.Department of PharmacyThe Hospital for Sick ChildrenTorontoCanada
  7. 7.Leslie Dan Faculty of PharmacyUniversity of TorontoTorontoCanada
  8. 8.Leeds Teaching Hospitals, NHS TrustSt. James’s University HospitalLeedsUK
  9. 9.Pediatric Hematology/OncologyJohann Wolfgang Goethe-University HospitalFrankfurtGermany

Personalised recommendations